Henatinib

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable, multitargeted tyrosine kinase inhibitor with potential antitumor and antiangiogenic activities. Upon administration, henatinib inhibits vascular endothelial growth factor receptor type 2 (VEGFR2), a tyrosine kinase receptor upregulated in many tumor cells that plays a key role in angiogenesis. This may result in an inhibition of angiogenesis and eventually tumor cell proliferation. Henatinib, structurally similar to sunitinib, also inhibits, though to a lesser extent, mast/stem cell growth factor receptor (c-Kit) and, platelet-derived growth factor receptor (PDGFR) alpha and beta.

**Synonyms:** - HENATINIB - Pyrrolo(3,2-c)azepin-4(1H)-one, 2-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-5,6,7,8-tetrahydro-5-((2R)-2-hydroxy-3-(4-morpholinyl)propyl)-3-methyl-